ReviewRegenerative biomaterials2016
Can microfluidics address biomanufacturing challenges in drug/gene/cell therapies?
Review in Regenerative biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- QbD product development: rapid optimization and scale-up of PBAE-based siRNA deliveryRSC pharmaceutics · 2026Article
- High-Throughput Microfluidic-Mediated Assembly of Layer-by-Layer Nanoparticles.Advanced functional materials · 2025Article
- Encapsulation of Therapeutic, Low-Molecular-Weight Chemokines Using a Single Emulsion, Microfluidic, Continuous Manufacturing Process.Pharmaceutics · 2025Article
- Non-viral delivery of CRISPR-Cas9 complexes for targeted gene editing via a polymer delivery system.Gene therapy · 2022Article
- Chips for Biomaterials and Biomaterials for Chips: Recent Advances at the Interface between Microfabrication and Biomaterials Research.Advanced healthcare materials · 2021Review
- Acoustofluidic Synthesis of Particulate Nanomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- A Review of State-of-the-Art Microfluidic Technologies for Environmental Applications: Detection and Remediation.Global challenges (Hoboken, NJ) · 2019Review
- Microfluidic fabrication of microparticles for biomedical applications.Chemical Society reviews · 2018Review
- Strategies for the enhanced intracellular delivery of nanomaterials.Drug discovery today · 2018Review
- Review
- The role of microfluidics in protein formulations with pre-programmed functional characteristics.Biologics : targets & therapy · 2018Review
- Robust manufacturing of lipid-polymer nanoparticles through feedback control of parallelized swirling microvortices.Lab on a chip · 2017Article
- Review
- Essential design considerations for the resazurin reduction assay to noninvasively quantify cell expansion within perfused extracellular matrix scaffolds.Biomaterials · 2017Article
- High-throughput screening of microchip-synthesized genes in programmable double-emulsion droplets.Nanoscale · 2017Article
- Cell-laden microfluidic microgels for tissue regeneration.Lab on a chip · 2016Review
- Efficient One-Step Production of Microencapsulated Hepatocyte Spheroids with Enhanced Functions.Small (Weinheim an der Bergstrasse, Germany) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Translation of any inventions into products requires manufacturing. Development of drug/gene/cell delivery systems will eventually face manufacturing challenges, which require the establishment of standardized processes to produce biologically-relevant products of high quality without incurring prohibitive cost. Microfluidicu technologies present many advantages to improve the quality of drug/gene/cell delivery systems. They also offer the benefits of automation. What remains unclear is whether they can meet the scale-up requirement. In this perspective, we discuss the advantages of microfluidic-assisted synthesis of nanoscale drug/gene delivery systems, formation of microscale drug/cell-encapsulated particles, generation of genetically engineered cells and fabrication of macroscale drug/cell-loaded micro-/nano-fibers. We also highlight the scale-up challenges one would face in adopting microfluidic technologies for the manufacturing of these therapeutic delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.